Under-reporting of pertussis in Ontario: A Canadian Immunization Research Network (CIRN) study using capture-recapture
Understanding the epidemiology of pertussis requires timely, reliable, and accurate surveillance data, but under-diagnosis and under-reporting of pertussis cases are longstanding challenges, compromising the ability to accurately estimate the burden of disease. Researchers aimed to estimate the true number of pertussis cases in Ontario separately in infants and those aged one year and over, and evaluate the completeness of each data source through a three-source capture-recapture data analysis.
Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine. However, children at increased risk for IMD should start immunization for serogroups B and C as soon as possible, assuming that they are at least 2 months of age.
Recorded video of SOGC webinar with Dr. Vanessa Poliquin.
Based on evidence reviewed and summarized in this advisory committee statement, the National Advisory Committee on Immunization makes recommendations on the use of previously recommended LZV and newly authorized RZV vaccine in populations and individuals.
Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000–2015
Reporting of adverse events following immunization (AEFI) is a key component for functional vaccine safety monitoring system. The aim of this study is to document trends in the AEFI reporting ratio globally and across the six World Health Organization (WHO) regions.
’Mise à jour complète du chapitre du Guide canadien d’immunisation : août 2018.
Although vaccination uptake is high in most countries, pockets of sub-optimal coverage remain, posing a threat to individual and population immunity. Increasingly, the term ‘vaccine hesitancy’ is being used by experts and commentators to explain sub-optimal vaccination coverage. The authors contend that using this term to explain all partial or non-immunization risks generating solutions that are a poor match for the problem in a particular community or population. The authors propose more precision in the term ‘vaccine hesitancy’ is needed, particularly since much under-vaccination arises from factors related to access or pragmatics.
Some people have worried that thimerosal, an ethylmercury-containing preservative in some multi-dose preparations of influenza vaccine, could cause mercury poisoning in children or affect the unborn children of pregnant women who receive this vaccine. But, for many reasons, thimerosal contained in vaccines is not harmful.
The Canadian Paediatric Society continues to encourage annual influenza vaccination for all children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2017/2018 influenza season are not substantially changed from those of last season. NACI has conducted a review of all available vaccine effectiveness data concerning live attenuated influenza vaccine (LAIV) and concludes that current evidence supports the continued use of LAIV in Canada, although use is not currently recommended in the USA because of concern about efficacy.
Vaccine recommendations for children and youth for the 2018/2019 influenza season: CPS Practice Point
The Canadian Paediatric Society continues to encourage annual influenza vaccination for all children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2018/2019 influenza season are not substantially changed from those of last season. Quadrivalent vaccine, if available, is recommended for children 6 months to 17 years of age. Either inactivated influenza vaccine or live attenuated influenza vaccine may be used for children and youth 2 to 17 years of age who are not immunocompromised.